Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement

Aug

22

Today In Oncology

Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk

Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses

FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices

Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma

Advertisement

© 2026 HSP News Service, L.L.C.